Research programme: CCR1 antagonists - ChemoCentryx
Alternative Names: CCX 634; CCX 9588Latest Information Update: 01 Dec 2022
At a glance
- Originator ChemoCentryx
- Class Small molecules
- Mechanism of Action CCR1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Rheumatoid arthritis
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Cancer in USA
- 18 Apr 2016 Updated pharmacodynamics data from a preclinical trial in Breast cancer presented at American Association for Cancer Research Annual Meeting (AACR-2016) ,
- 04 Nov 2015 Preclinical trials in Cancer in USA (unspecified route)